Another limitation is that we compared only the efficacy of the two anti-VEGF agents Recently, as the third agent for ROP treatment, a large clinical trial was performed to evaluate the efficacy of aflibercept [12]. The gene discussed is VEGFA; the disease is retinopathy of prematurity.